<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01212458</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.03</org_study_id>
    <nct_id>NCT01212458</nct_id>
  </id_info>
  <brief_title>Effect of Oral Rufinamide and Oxcarbazepine on Nerve Excitability, Hyperalgesia, Allodynia and Flare Reaction Compared to Placebo. A Monocenter, Randomized, Double-blind, Cross-over Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Zurich</source>
  <brief_summary>
    <textblock>
      Untersuchungen über die Wirkmechanismen von Antiepileptika haben gezeigt, dass durch eine&#xD;
      Blockierung von spannungsabhängigen Natrium-Kanälen im Nervensystem die Schmerzübertragung&#xD;
      moduliert werden kann. Verschiedene Antiepileptika werden in der chronischen Schmerztherapie&#xD;
      schon lange angewendet (z.B. Oxcarbazepinum, Trileptal ® bei Trigeminusneuralgie oder&#xD;
      diabetischer Polyneuropathie).&#xD;
&#xD;
      In unserer Untersuchung wollen wir zwei in der Schweiz zugelassene Antiepileptika bezüglich&#xD;
      ihrer Wirkung auf das Schmerzempfinden untersuchen. Eines dieser Medikamente, Trileptal®&#xD;
      (Wirkstoff: Oxcarbazepinum), wird schon häufig bei chronischen Schmerzzuständen eingesetzt.&#xD;
      Das zweite Medikament, Inovelon® (Wirkstoff: Rufinamid) ist seit mehr als einem Jahr in der&#xD;
      Schweiz zugelassen und wird klinisch vor allem in der Behandlung von besonderen&#xD;
      Epilepsieformen im Kindesalter eingesetzt. Wir erwarten, dass auch nach Gabe von Inovelon®&#xD;
      die Schmerzleitung in den Nervenzellen verändert und die lokalen Schmerzreaktionen in der&#xD;
      Haut vermindert werden.&#xD;
&#xD;
        -  Trial with medicinal product&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy Subjects</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rufinamid</intervention_name>
    <description>Effect of oral rufinamide and oxcarbazepine on nerve excitability, hyperalgesia, allodynia and flare reaction compared to placebo.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        healthy volunteers&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria: Male&#xD;
&#xD;
          -  Age: 18-65 years&#xD;
&#xD;
          -  Weight: 50 - 100 kg&#xD;
&#xD;
          -  Height: 155 - 195 cm&#xD;
&#xD;
          -  Signed and dated informed consent&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Contraindications to the class of drugs under study&#xD;
&#xD;
          -  Intellectually or mental impaired subjects&#xD;
&#xD;
          -  Known hypersensitivity to class of drugs or the investigational product&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Known peripheral neuropathies&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Chronic alcohol consumption&#xD;
&#xD;
          -  Congestive heart disease&#xD;
&#xD;
          -  Participants of other studies during study period and 30 days prior to study begin&#xD;
&#xD;
          -  Smoker&#xD;
&#xD;
          -  Abnormal electrocardiogram&#xD;
&#xD;
          -  Any regular concomitant medication&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Konrad Maurer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Institut of Anaesthesiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich, Institut of Anaesthesiology</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <study_first_submitted>September 29, 2010</study_first_submitted>
  <study_first_submitted_qc>September 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2010</study_first_posted>
  <last_update_submitted>March 14, 2014</last_update_submitted>
  <last_update_submitted_qc>March 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>gesunde Probanden</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

